NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 3 filers reported holding NOVOCURE LTD in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $438,117 | -90.8% | 27,128 | -76.5% | 0.00% | -90.0% |
| Q2 2023 | $4,781,879 | -37.8% | 115,226 | -9.8% | 0.03% | -36.2% |
| Q1 2023 | $7,682,524 | -22.8% | 127,744 | -5.9% | 0.05% | -13.0% |
| Q4 2022 | $9,956,749 | -21.3% | 135,743 | -18.5% | 0.05% | -15.6% |
| Q3 2022 | $12,651,000 | +20.2% | 166,502 | +9.9% | 0.06% | +42.2% |
| Q2 2022 | $10,527,000 | -6.8% | 151,470 | +11.1% | 0.04% | -2.2% |
| Q1 2022 | $11,291,000 | +51.3% | 136,280 | +37.1% | 0.05% | +7.0% |
| Q4 2021 | $7,463,000 | -33.2% | 99,401 | +3.4% | 0.04% | -29.5% |
| Q3 2021 | $11,165,000 | -47.9% | 96,106 | -0.6% | 0.06% | -55.8% |
| Q2 2021 | $21,437,000 | – | 96,642 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $39,681,000 | 20.12% |
| HARTLINE INVESTMENT CORP/ | 330,672 | $27,866,000 | 5.97% |
| MORGAN JESS S & CO INC | 52,889 | $4,457,000 | 4.37% |
| Darsana Capital Partners LP | 1,350,000 | $113,765,000 | 3.88% |
| Rhenman & Partners Asset Management AB | 350,000 | $29,495,000 | 3.23% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $843,000 | 2.55% |
| Taylor Frigon Capital Management LLC | 38,073 | $3,208,000 | 2.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,500 | $2,991,000 | 1.08% |
| Granite Investment Partners, LLC | 261,315 | $22,021,000 | 1.04% |
| Nicholas Investment Partners, LP | 85,835 | $7,233,000 | 0.74% |